Low platelet iPLA(2) activity predicts conversion from mild cognitive impairment to Alzheimer's disease: a 4-year follow-up study

Imagem de Miniatura
Arquivos
art_GATTAZ_Low_platelet_iPLA(2)_activity_predicts_conversion_from_mild_2014.PDF (278.96 KB)
Citações na Scopus
28
Tipo de produção
article
Data de publicação
2014
Editora
SPRINGER WIEN
DOI
Indexadores
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Autores
DINIZ, Breno S.
Autor de Grupo de pesquisa
Editores
Coordenadores
Organizadores
Citação
JOURNAL OF NEURAL TRANSMISSION, v.121, n.2, p.193-200, 2014
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Reduced phospholipase A(2) (PLA(2)) activity has been reported in the brain and in blood cells of patients with Alzheimer's disease (AD). Individuals with mild cognitive impairment (MCI) are at increased risk of developing AD. In the present study, we determined the activity of distinct PLA(2) subgroups (iPLA(2), sPLA(2) and cPLA(2)) in older adults with MCI as compared to patients with mild dementia due to AD and to cognitively healthy controls. We investigated whether decreased PLA(2) activity at baseline is associated with the progression of MCI to AD upon follow-up during a period of 4 years. The activity of PLA(2) subgroups was determined in platelets from 169 elderly adults. Progression of MCI to AD was ascertained by standard clinical criteria for AD upon follow-up. At baseline, iPLA(2) activity was significantly decreased (p = 0.001) in patients with AD and MCI as compared to controls. Patients with MCI who progressed to AD during follow-up showed significantly lower iPLA(2) activity at baseline as compared to patients with MCI who did not progress to AD (p = 0.009). Moreover, subjects from the control group at baseline who progressed to MCI during follow-up had lower sPLA(2) and cPLA(2) (p = 0.014 and p = 0.009, respectively). Our findings suggest that low platelet iPLA(2) activity may be a risk marker for AD in subjects with MCI. Moreover, low sPLA(2) and cPLA(2) were related to cognitive decline in healthy controls, suggesting a relationship with the very early stages of the disease.
Palavras-chave
Phospholipase A(2), Alzheimer's disease, Mild cognitive impairment
URI
https://observatorio.fm.usp.br/handle/OPI/5434
Referências
  1. Arioka M, 2005, FEBS LETT, V579, P2693, DOI 10.1016/j.febslet.2005.03.092
  2. Bakken AM, 2006, PLATELETS, V17, P484, DOI 10.1080/09537100600759196
  3. Bianchi M, 2002, EXP BRAIN RES, V143, P191, DOI 10.1007/s00221-001-0979-3
  4. Buchhave P, 2010, NEUROBIOL AGING, V31, P1877, DOI 10.1016/j.neurobiolaging.2008.10.012
  5. Burke JE, 2009, J LIPID RES SS2, V50, P37
  6. Chalbot S, 2009, CLIN CHEM, V55, P2171, DOI 10.1373/clinchem.2009.130286
  7. Cho HW, 2006, NEUROSCI LETT, V397, P214, DOI 10.1016/j.neulet.2005.12.014
  8. Colangelo V, 2002, J NEUROSCI RES, V70, P462, DOI 10.1002/jnr.10351
  9. DENNIS EA, 1994, J BIOL CHEM, V269, P13057
  10. De-Paula VJ, 2010, PROSTAG LEUKOTR ESS, V82, P57, DOI 10.1016/j.plefa.2009.07.006
  11. Diniz BS, 2010, J ALZHEIMERS DIS, V22, P1305, DOI 10.3233/JAD-2010-100921
  12. EMMERLING MR, 1993, BIOCHEM BIOPH RES CO, V197, P292, DOI 10.1006/bbrc.1993.2474
  13. Emmerling MR, 1996, ANN NY ACAD SCI, V777, P310, DOI 10.1111/j.1749-6632.1996.tb34438.x
  14. Farooqui AA, 2004, PROSTAG LEUKOTR ESS, V71, P161, DOI 10.1016/j.plefa.2004.03.004
  15. FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
  16. Fonteh AN, 2013, J LIPID RES
  17. Forlenza OV, 2002, J NEURAL TRANSM, V109, P623, DOI 10.1007/s007020200051
  18. Forlenza OV, 2007, PROSTAG LEUKOTR ESS, V76, P47, DOI 10.1016/j.plefa.2006.10.002
  19. Forlenza OV, 2007, J NEURAL TRANSM, V114, P231, DOI 10.1007/s00702-006-0597-0
  20. Forlenza OV, 2005, PSYCHOPHARMACOLOGY, V180, P359, DOI 10.1007/s00213-005-2168-8
  21. Forlenza OV, 2010, REV BRAS PSIQUIATR, V32, P216, DOI 10.1590/S1516-44462010005000002
  22. Forlenza OV, 2009, DEMENT GERIATR COGN, V28, P507, DOI 10.1159/000255051
  23. GATTAZ WF, 1995, BIOL PSYCHIAT, V37, P13, DOI 10.1016/0006-3223(94)00123-K
  24. Gattaz WF, 2004, J NEURAL TRANSM, V111, P591, DOI 10.1007/s00702-004-0142-y
  25. Gattaz WF, 1996, EUR ARCH PSY CLIN N, V246, P129, DOI 10.1007/BF02189113
  26. Heneka MT, 2010, J NEURAL TRANSM, V117, P919, DOI 10.1007/s00702-010-0438-z
  27. Ikeno Y, 2005, J BIOL CHEM, V280, P28044, DOI 10.1074/jbc.M503343200
  28. Krzystanek E, 2007, J NEURAL TRANSM, V114, P1033, DOI 10.1007/s00702-007-0669-9
  29. Lambeau G, 2008, ANNU REV BIOCHEM, V77, P495, DOI 10.1146/annurev.biochem.76.062405.154007
  30. Masuda S, 2005, J BIOL CHEM, V280, P23203, DOI 10.1074/jbc.M500985200
  31. Masuda S, 2008, BIOCHEM J, V409, P429, DOI 10.1042/BJ20070844
  32. MCKHANN G, 1984, NEUROLOGY, V34, P939
  33. Moses GSD, 2006, J NEUROINFLAMM, V3, DOI 10.1186/1742-2094-3-28
  34. Nitsch RM, 1997, J NEUROCHEM, V69, P704
  35. Nordberg A, 2006, ALZ DIS ASSOC DIS, V20, pS12, DOI 10.1097/01.wad.0000213804.59187.2d
  36. Nunes PV, 2008, INT J GERIATR PSYCH, V23, P1127, DOI 10.1002/gps.2038
  37. Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303
  38. PETTEGREW JW, 1988, J NEUROPATH EXP NEUR, V47, P235, DOI 10.1097/00005072-198805000-00004
  39. ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698
  40. Schaeffer E, 2009, J NEURAL TRANSM, V116, P41, DOI 10.1007/s00702-008-0133-5
  41. Schaeffer EL, 2007, J NEURAL TRANSM, V114, P379, DOI 10.1007/s00702-006-0585-4
  42. Schaeffer EL, 2008, PSYCHOPHARMACOLOGY, V198, P1, DOI 10.1007/s00213-008-1092-0
  43. Schaeffer EL, 2011, PROG NEURO-PSYCHOPH, V35, P1612, DOI 10.1016/j.pnpbp.2011.05.001
  44. Schaeffer EL, 2010, PROG NEURO-PSYCHOPH, V34, P1381, DOI 10.1016/j.pnpbp.2010.08.019
  45. Schaeffer EL, 2012, CURR TOP MED CHEM, V12, P2314
  46. Schaeffer EL, 2005, PSYCHOPHARMACOLOGY, V181, P392, DOI 10.1007/s00213-005-2256-9
  47. Schaeffer EL, 2009, PSYCHOPHARMACOLOGY, V202, P37, DOI 10.1007/s00213-008-1351-0
  48. Schaeffer EL, 2011, J NEURAL TRANSM, V118, P1273, DOI 10.1007/s00702-011-0619-4
  49. Schaloske RH, 2006, BBA-MOL CELL BIOL L, V1761, P1246, DOI 10.1016/j.bbalip.2006.07.011
  50. Smallheiser NR, 1996, BRAIN RES, V721, P39, DOI 10.1016/0006-8993(96)00134-5
  51. Stephenson D, 1999, GLIA, V27, P110, DOI 10.1002/(SICI)1098-1136(199908)27:2<110::AID-GLIA2>3.0.CO;2-C
  52. Stephenson DT, 1996, NEUROBIOL DIS, V3, P51, DOI 10.1006/nbdi.1996.0005
  53. Sun GY, 2010, NEUROMOL MED, V12, P133, DOI 10.1007/s12017-009-8092-z
  54. Sun GY, 2004, J LIPID RES, V45, P205, DOI 10.1194/jlr.R300016-JLR200
  55. Talbot K, 2000, NEUROCHEM INT, V37, P17, DOI 10.1016/S0197-0186(00)00006-1
  56. Talib LL, 2013, PROSTAGLANDINS LEUKO, DOI [10.1016/j.plefa.2013.07.002, DOI 10.1016/J.PLEFA.2013.07.002.[]
  57. Talib LL, 2012, PROSTAG LEUKOTR ESS, V86, P149, DOI 10.1016/j.plefa.2012.02.005
  58. Talib LL, 2008, PROSTAG LEUKOTR ESS, V78, P265, DOI 10.1016/j.plefa.2008.03.002

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/27